Dexcom Stelo: The First Over-the-Counter Continuous Glucose Monitor

For the first time in history, anyone can buy a continuous glucose monitor without a prescription. What this means for the future of preventive metabolic health.

Presented By Our Partners

Until 2024, continuous glucose monitors existed behind a gatekeeping wall. You needed a diabetes diagnosis. You needed a prescription. You needed insurance to justify the cost. The technology that could reveal the most granular picture of your metabolic health was, by regulatory design, available only to people who were already sick. Millions of Americans with rising fasting glucose, undiagnosed insulin resistance, or early metabolic dysfunction had no practical access to the tool that could show them what was happening inside their bodies in real time.

That wall came down when the FDA cleared the Dexcom Stelo as the first over-the-counter continuous glucose monitor. No prescription. No diabetes diagnosis. No insurance gatekeeping. For approximately $99 per month, any adult can now wear a clinical-grade glucose sensor and see, minute by minute, how their body responds to food, exercise, stress, and sleep. The implications for preventive medicine are difficult to overstate. A 2024 study published in Nature Medicine by Shilo and colleagues placed CGMs on 8,315 nondiabetic adults and found that 40% of those initially classified as having normal fasting glucose would have been reclassified as prediabetic based on sequential measurements. The metabolic dysfunction was already there. It was simply invisible without continuous monitoring.

The Dexcom Stelo makes that invisible dysfunction visible, and it puts the power of detection in the consumer’s hands rather than the healthcare system’s.

What Is the Dexcom Stelo?

The Dexcom Stelo is a continuous glucose monitoring system designed specifically for the over-the-counter wellness market. It measures interstitial glucose through a small sensor worn on the back of the upper arm, providing a new reading every five minutes. Each sensor lasts 15 days, which is five days longer than the prescription-only Dexcom G7, making it the longest-wear Dexcom sensor currently available.

The Stelo streams glucose data to a companion smartphone app that displays the current glucose level, a trend arrow indicating the direction of change, and an eight-hour trace of glucose history. The app also provides daily and weekly summaries, meal tagging, and basic pattern recognition to help users understand how their dietary choices and activities affect glucose dynamics.

Unlike the Dexcom G7, the Stelo does not include low glucose (hypoglycemia) alerts, reflecting its regulatory positioning as a wellness device rather than a diabetes management tool. It is cleared for adults aged 18 and older who are not using insulin, which encompasses the vast majority of the prediabetic and metabolically curious population. The device is available for purchase directly through Dexcom’s website and select retail channels without a prescription.

The Stelo uses a simplified single-piece applicator identical to the G7, is waterproof for up to 8 feet of water for 24 hours, and requires no calibration fingersticks. It is HSA and FSA eligible.

The Science Behind Continuous Glucose Monitoring for Wellness

The clinical rationale for continuous glucose monitoring in nondiabetic populations rests on a growing body of evidence that standard glucose testing dramatically underestimates the prevalence of metabolic dysfunction. The 2024 Nature Medicine study by Shilo et al. is the most compelling demonstration of this gap. Among 8,315 nondiabetic adults wearing CGMs, the researchers documented a mean fasting glucose of 96.2 mg/dL with a day-to-day individual standard deviation of 7.52 mg/dL. This variability means that a single fasting glucose measurement is essentially a coin flip for individuals near the diagnostic threshold of 100 mg/dL.

The finding that 40% of initially “normal” individuals would have been reclassified as prediabetic on sequential measurements suggests that metabolic dysfunction exists on a spectrum that point-in-time testing cannot capture. CGM reveals this spectrum by providing hundreds of data points per day, exposing postprandial spikes, nocturnal patterns, and the glucose impact of exercise, sleep quality, and stress that a single lab draw cannot show.

Glycemic variability, the magnitude and frequency of glucose fluctuations, has emerged as a risk factor independent of average glucose levels. Research from the broader medical research community has linked high glycemic variability to increased oxidative stress, endothelial dysfunction, and inflammatory cascades that contribute to cardiovascular disease and accelerated biological aging. A person with an “average” glucose of 95 mg/dL who regularly spikes to 160 mg/dL after meals may face more metabolic stress than someone with a steady 100 mg/dL, even though the first person’s average looks better on paper.

The practical value of CGM for wellness users lies in the behavioral feedback loop it creates. When you can see that a bowl of white rice pushes your glucose to 155 mg/dL while the same portion of brown rice peaks at 120 mg/dL, or that a 20-minute walk after dinner flattens your postmeal spike by 30 mg/dL, you gain actionable intelligence that no amount of general dietary advice can provide. Metabolic responses to food are highly individual, influenced by genetics, gut microbiome composition, sleep history, stress levels, and physical activity. CGM reveals your personal response pattern, enabling dietary and lifestyle optimization that is genuinely personalized rather than population-averaged.

A 2024 study in Nature Communications by Brandhorst et al. demonstrated that dietary interventions targeting metabolic health reduced biological age by an average of 2.5 years. CGM provides the feedback mechanism to guide and verify such interventions at the individual level.

That is the science. Here is how the Dexcom Stelo applies it.

What the Dexcom Stelo Does Well

The Stelo’s most important achievement is regulatory: it is the first CGM that anyone can buy without navigating the healthcare system. This eliminates the prescription barrier, the insurance pre-authorization process, and the implicit requirement of a diabetes diagnosis. For the tens of millions of Americans with undiagnosed prediabetes or early metabolic dysfunction, the Stelo represents a direct path to visibility into their own glucose biology.

The 15-day sensor wear is a practical advantage over the G7’s 10-day duration. Fewer sensor changes mean lower ongoing friction and a better user experience for wellness-oriented individuals who may be less motivated than insulin-dependent diabetics to maintain a strict replacement schedule. Two sensors cover an entire month of monitoring, simplifying the logistics and inventory management.

At approximately $99 per month, the Stelo is priced aggressively below the G7’s $350 to $400 cash cost. This positions it as a viable option for consumers who want to explore CGM without committing to a premium clinical device. The pricing is competitive with or below several CGM-as-a-service platforms that add software layers on top of the same underlying sensor technology.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The app experience is clean and accessible, designed for users who may be new to glucose monitoring. Daily summaries, meal tagging, and trend visualization provide enough context for beginners to start understanding their glucose patterns without requiring prior health literacy. The absence of hypoglycemia alerts simplifies the experience by removing clinical features that wellness users do not need.

Pricing, Access, and Practical Realities

The Dexcom Stelo costs approximately $99 per month for two 15-day sensors, with no additional subscription fee for the companion app. This is the total cost of ownership: sensor hardware plus software access. There is no separate app subscription, membership fee, or coaching charge. First-year cost of ownership is approximately $1,188.

The device is available over the counter without a prescription, which is the single most important differentiator from the Dexcom G7 and the Abbott FreeStyle Libre 3 (which require prescriptions for standard purchase). Purchase channels include Dexcom’s own website and select retail locations.

The Stelo is HSA and FSA eligible, allowing consumers to pay with pre-tax healthcare dollars. This effectively reduces the real monthly cost to approximately $65 to $80 depending on the individual’s tax bracket.

The device is FDA cleared as an over-the-counter CGM for adults aged 18 and older who are not using insulin. This regulatory positioning places it squarely in the general wellness category. It is not cleared for insulin dosing decisions, diabetes diagnosis, or treatment monitoring. Users with insulin-dependent diabetes should use the Dexcom G7 or another prescription CGM instead.

Practically, the Stelo requires a compatible smartphone (iPhone or Android) for display and data storage. There is no standalone receiver option. The sensor is applied to the back of the upper arm using a simple auto-applicator and requires no calibration fingersticks. It is waterproof and designed for continuous wear during all daily activities including showering, swimming, and exercise.

Who the Dexcom Stelo Is Best For

The Stelo is ideal for metabolically curious individuals who want to understand how their body processes glucose without navigating the prescription system. It is particularly well suited for adults with a family history of type 2 diabetes who want to monitor their glucose trends proactively, individuals exploring dietary strategies like intermittent fasting or low-carbohydrate eating who want to validate their approach with objective data, and athletes or fitness enthusiasts who want to understand how training, recovery, and nutrition interact with glucose dynamics.

The device also works well as a short-term diagnostic experiment. Some users wear a CGM for one to three months to establish their baseline glucose patterns, identify problematic foods, and build an evidence-based dietary framework, then discontinue monitoring once they have the information they need. The absence of a long-term subscription commitment makes this approach financially practical.

Consumers who may want to skip the Stelo include individuals with insulin-dependent diabetes (the Stelo lacks hypoglycemia alerts and is not cleared for insulin dosing). People who want advanced analytics, metabolic scoring, food response grading, or registered dietitian coaching should consider platforms like Levels Health or Nutrisense, which layer software intelligence on top of CGM sensors. Those on the tightest budgets may find $99 per month more than they want to spend on wellness monitoring and might consider periodic blood testing through direct-access labs as a lower-cost alternative.

How the Dexcom Stelo Compares

The Dexcom G7 is the Stelo’s prescription-grade sibling. It offers a 10-day sensor (versus 15), hypoglycemia alerts, insulin dosing clearance, and direct-to-watch connectivity. The G7 costs $350 to $400 per month at the cash price. For nondiabetic wellness users, the Stelo provides the core glucose monitoring experience at roughly one-quarter of the G7’s cost. For diabetic users who need alerts and dosing clearance, the G7 remains the appropriate choice.

The Abbott FreeStyle Libre 3 is a prescription CGM with a 14-day sensor, real-time streaming, and a cash price of $75 to $235 per month. It is comparable to the Stelo in sensor technology and accuracy but requires a prescription. The Libre 3 includes glucose alerts, which the Stelo omits. For users who can obtain a prescription, the Libre 3 may offer a slightly lower cost with broader clinical features. For users who want to avoid the prescription process entirely, the Stelo is the clear choice.

Levels Health, Nutrisense, and Signos are CGM-as-a-service platforms that pair CGM sensors (typically Dexcom or Libre) with proprietary software, analytics, and in some cases registered dietitian coaching. These platforms cost $199 to $399 per month, significantly more than the Stelo alone. The added value is in the software layer: metabolic scoring, food response analysis, personalized recommendations, and coaching support. Users who want raw CGM data at the lowest cost should choose the Stelo. Those who want curated analytics and coaching should consider the platform services.

Limitations and Open Questions

The Stelo’s most significant limitation is the absence of low glucose (hypoglycemia) alerts. This is a deliberate regulatory design choice reflecting its wellness positioning, but it means the device is inappropriate for anyone at risk of clinically dangerous low blood sugar events. Individuals with insulin-dependent diabetes or those taking sulfonylureas should not rely on the Stelo for glucose management.

The companion app, while clean and accessible, lacks the advanced analytics that power users may want. There is no metabolic scoring system, no AI-driven food response grading, no biological age estimation, and no integration with registered dietitian coaching. Users who want these features will need to pair the Stelo with a third-party analytics platform or switch to a service like Levels Health.

Clinical evidence for CGM in nondiabetic populations is growing but not yet definitive. While the Shilo et al. 2024 study and others support the value of continuous glucose data for identifying metabolic dysfunction, large-scale randomized controlled trials demonstrating that CGM use by healthy individuals leads to improved long-term health outcomes have not yet been published. The Stelo’s value proposition is currently supported more by physiological reasoning and observational data than by outcomes-level evidence.

Sensor accuracy, while strong, involves the same 5 to 15 minute interstitial lag that affects all CGMs. During rapid glucose changes, the displayed reading may not precisely match a simultaneous blood glucose measurement.

What This Means for Your Health

The Dexcom Stelo represents a fundamental shift in who gets access to metabolic health data. Within Healthcare Discovery‘s longevity framework, glucose monitoring connects directly to the nutrition pillar, providing real-time feedback on how food choices affect blood sugar. But the connections extend further. Sleep quality shows up in morning glucose levels and overnight glycemic stability. Movement, particularly post-meal walks and structured exercise, produces visible glucose-lowering effects that CGM can quantify. Even stress and breathwork practices have measurable glucose signatures, as cortisol-driven stress responses elevate blood sugar independently of food intake.

Metabolic dysfunction is one of the Four Shadows that the broader medical research community identifies as the primary chronic disease threats to longevity. Insulin resistance does not begin on the day of a diabetes diagnosis. It develops over years, progressing through stages of postmeal glucose spikes, rising fasting glucose, and declining insulin sensitivity that are invisible on standard annual lab work. CGM makes these early signals visible, creating the opportunity for intervention during the window when lifestyle changes are most effective.

The Stelo does not diagnose disease, and wearing a CGM does not guarantee better health outcomes. What it does is provide information: a continuous stream of personal metabolic data that enables you to make evidence-based decisions about how you eat, when you move, and how well you recover. At $99 per month with no prescription required, it is the most accessible entry point to continuous glucose monitoring available today. For individuals who believe that managing what you measure is more effective than managing what you guess, the Stelo is a meaningful tool for building a proactive metabolic health practice.

Frequently Asked Questions

Do I need a prescription for the Dexcom Stelo?

No. The Dexcom Stelo is the first FDA-cleared over-the-counter continuous glucose monitor. Any adult aged 18 and older who does not use insulin can purchase it directly without a prescription. It is available through Dexcom’s website and select retail locations. This is a significant departure from traditional CGMs like the Dexcom G7 and Abbott FreeStyle Libre 3, which require prescriptions.

How much does the Dexcom Stelo cost?

The Stelo costs approximately $99 per month for two 15-day sensors. There is no additional app subscription or membership fee. First-year total cost is approximately $1,188. The device is HSA and FSA eligible, which can reduce the effective cost to $65 to $80 per month after tax savings. No insurance billing is involved.

What is the difference between the Dexcom Stelo and the Dexcom G7?

The G7 is a prescription CGM for diabetes management ($350 to $400/month, 10-day sensor, hypoglycemia alerts, insulin dosing clearance, watch connectivity). The Stelo is an OTC wellness CGM ($99/month, 15-day sensor, no hypo alerts, no insulin dosing clearance). For nondiabetic wellness monitoring, the Stelo provides core glucose tracking at roughly one-quarter of the G7’s cost.

Can the Dexcom Stelo detect prediabetes?

The Stelo is classified as a general wellness device and is not cleared to diagnose prediabetes, diabetes, or any medical condition. However, it provides continuous glucose data that can reveal patterns consistent with metabolic dysfunction, such as frequent postmeal spikes above 140 mg/dL or elevated fasting glucose. If you observe concerning patterns, consult a healthcare provider for formal diagnostic testing.

How long does each Dexcom Stelo sensor last?

Each Stelo sensor lasts 15 days, which is five days longer than the Dexcom G7’s 10-day sensor. Two sensors cover a full month of continuous monitoring. The sensor is applied to the back of the upper arm using a simple auto-applicator and requires no calibration fingersticks. It is waterproof and designed for continuous wear.

Is the Dexcom Stelo accurate enough for health decisions?

The Stelo uses Dexcom’s proven sensor technology with accuracy comparable to the G7. It provides a reliable picture of glucose trends, postmeal responses, and daily patterns. However, it measures interstitial fluid (not blood directly), which introduces a 5 to 15 minute lag during rapid glucose changes. It is accurate enough to inform dietary and lifestyle decisions but should not be used for insulin dosing or medical treatment decisions.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.